Mirum Pharmaceuticals News

Express News | Mirum Pharmaceuticals Inc -Additionally, Livmarli Received Favorable Comp Opinion Recommending Maintenance of Orphan Drug Designation in Pfic

BreakingsMay 31 07:30

Mirum Pharmaceuticals Announces Positive Evaluation of Pfic's Livmarli (Maralixibat) Oral Solution for the Treatment of Patients 3 Months and Older

Mirum Pharmaceuticals Announces Positive Evaluation of Pfic's Livmarli (Maralixibat) Oral Solution for the Treatment of Patients 3 Months and Older

Zhitong FinanceMay 31 07:30

Express News | Mirum Pharmaceuticals Inc -Following Chmp and Comp Opinions, a Decision by European Commission Is Expected in Q3 of 2024

BreakingsMay 31 07:30

Express News | Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older

BreakingsMay 31 07:30

Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now

Yahoo FinanceMay 30 06:37

Mirum Pharmaceuticals To Present Long-Term Data From Its LIVMARLI Studies In ALGS And PFIC At EASL Congress

Mirum Pharmaceuticals To Present Long-Term Data From Its LIVMARLI Studies In ALGS And PFIC At EASL Congress

BenzingaMay 29 07:38

Mirum Pharmaceuticals Insiders Sold US$954k Of Shares Suggesting Hesitancy

A number of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insiders sold their shares in the last year, which may have raised concerns among investors. When analyzing insider transactions, it is usually

Simply Wall StMay 28 06:55

Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo

Seeking AlphaMay 25 09:24

Stifel Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $48

Stifel analyst Dae Gon Ha maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 36.2% and a

Futu NewsMay 24 06:31

Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)

TipRanksMay 24 06:11

Cantor Fitzgerald Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $45

Cantor Fitzgerald analyst Joshua Schimmer maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and adjusts the target price from $40 to $45.According to TipRanks data, the analyst has a succe

Futu NewsMay 23 09:31

Reported Saturday, Mirum Pharmaceuticals' LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC

Presented by Professor Richard J. Thompson, MD, King's College London, United KingdomPatients with PFIC showed significant and sustained improvements in pruritus severity, serum bile acid (sBA) levels

BenzingaMay 20 01:06

Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting

- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring

BusinesswireMay 18 06:00

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase

BusinesswireMay 10 18:30

Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss

Yahoo FinanceMay 10 12:55

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow JonesMay 10 10:53

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Lowers Price Target to $53

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals with a Overweight and lowers the price target from $57 to $53.

Analyst UpgradesMay 10 10:43

Positive Outlook for Mirum Pharmaceuticals With Buy Rating Amid Upcoming Catalysts and Robust Financials

TipRanksMay 10 00:29

Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities

Mirum Pharmaceuticals Is Maintained at Market Outperform by JMP Securities

Dow JonesMay 9 13:49

Citibank: Maintains the Mirum Pharmaceuticals (MIRM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $37.00 to $38.00.

Citibank: Maintains the Mirum Pharmaceuticals (MIRM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $37.00 to $38.00.

Zhitong FinanceMay 9 12:50